Looks like you are in denial.
It is clear that you have sold your soul to the Devil Hedgie Shorts. Hope you feel good about who you are and what you do.
Also, keep your eyes on Claims 5 - 9. Judge Navarro in Nevada ruled that these patent claims were invalid as a matter of law and SPPI did not even get to argue the factual validity. That ruling alone could cause the entire decision to be overturned.
Yekafena, short babbling and you should each please go double check the solvency of the hedge funds who are paying you. They have to be in the final stages of serious budget cuts as evidenced by your posts on this message board.
Really, you should check right away because they will toss you to the curb in a heartbeat when their investors pull their funds. Things are not right and the budget is being shredded to the breaking point.
Three important follow-up questions:
1. Did you see Raj at all in your dream and, most importantly, was he there when you woke up?
2. Did you also happen to see Venice at all in the dream?
3. Could you tell what year it was?
We will see if we can "figure this out" a little more. TIA
iome, iome, iome,
really? You do not have a clue.
First, it is "injunction" not "injection" in the United States.
Second, do you have any idea as to what SPPI's burden of proof is in the Motion for a Permanent Injunction in order to have any chance of being successful? Please do some research and then you will have a better understanding. TIA
There are other game changing events as well:
1. Sandoz loses the May 18th Orphan Drug case and can't sell 175 or 250 mg vials for colorectal cancer.
2. Sandoz loses the Federal Circuit case and the patent is upheld.
3. CE Meph sales are meaningful.
4. Apaz receives Panel Review and a recommendation of approval.
5. SPI-2012 preliminary Phase III data reconfirms Phase II bioequivalent or better.
6. Poziotinib is still a little to far away but good Phase II will increase any future buyout price dramatically.
Problem is, the Sandoz cases and CE Melph are the only 3 opportunities this year.
Good article Zeus. Written by Martin Lipton, a serious NY M&A attorney. I think the heat will be turned up a lot and it will get real interesting if:
1. Another hedge or Tute publicly supports Armistice and also files a 13F; or
2. Armistice notices a Special Shareholders' Meeting; or
3. A hostile buyout offer is announced.
Any of those and show is on. The best thing SPPI can do is get those Apaz and SPI-2012 trials going, forget that Comp plan and hope CE Melph is approved early.
Imho, ville, iome, sts, biosht, db,
You guys have a serious case of p enis envy. If you really want to see it, please come to the shareholders’ meeting and I will show you how big it is. Trust me, it is bigger than yours. Have a great weekend, Joe
Now, you are starting to think ville. The answer could be the very worst nightmare for you and the shorts.
Thusm I will ask you a question: Why does SPPI's Corporate May Presentation not mention any Phase III for Apaziquone and only an NDA filing unlike the repeated references and milestone mentions of Phase III and II study commencements for SPI-2012 and Poziotinib. No mention at all of any Apaz study. Simply an NDA filing.
You don't think the FDA is letting SPPI merely combine its prior Phase III data from the prior years and show the effect without blood in the bladder do you? Hence, re-submit data and re-file.
Incorrect once again.
Also, when the market drops 30%, your UPRO will go to Zero and your account will be closed. That is what Triple Margin does. just sayin
Iome. Sell your shares and move on. You have lost sight of reality altogether and do not have the fortitude to see SPPI's future nor do you deserve to share in it.
Problem is....they are the JV team. Also, they have Alzheimer's as they cannot even remember what they say day to day much less several days ago.
As a result, there is no consistency or substance to their game plan. Even cigan could help teach them a little which is a "big" statement. These must be the small Hedgie's JV team. embarrassing.
1. The Noteholders can convert early but SPPI generally has NO right to redeem or prepay the Notes prior to the December 15, 2018 Maturity Date. Exhibit 4.1, Article 4.
2. SPPI also entered into a warrant hedge agreement with RBC so there would be Zero Dilution below $14.03 PPS which was 70% above the PPS at closing. Thus, the conversion is at $10.53 but if the PPS is higher, then the dilution only hurts to the extent the PPS is above $14.03. Form 8-K, Page 3, paragraph 5.
Please confirm, but it would seem:
1. Pull the rug out from under the Noteholders so there is no possibility that they will receive shares if the PPS is above the $10.53 agreed conversion price. Thus, their upside hedge on their short position is effectively gone. Plus, they no longer have any assurance they will receive anything other than a repayment of their loan in Cash only.
2. Continue to drive Revenues and Earnings Growth with CE MELPH, APAZ, SPI-2012 and P results and/or NDA approvals.
3. If PPS, is $30, $40, $80 by December 2018, (i) enter into a Line of Credit and pay them in cash or (ii) do a small secondary at $80 for 1.5 million shares and pay them off.
Take a look at page 57 of Exhibit 4.1. Complicated, but there is an adjustment from the $10.53 PPS Conversion Rate price per share under 11.03(b)(v)(B) for all cash settlements or combination settlements under subsection (C).